March 27th, 2015
Fighting the Contradiction: A Hospital Rolls Out the Red Carpet for Smokers
Jean-Pierre Usdin, MD
Jean-Pierre Usdin is frustrated with his “Tobacco-Free” hospital’s accommodations for smokers that encourage them to keep smoking instead of supporting them to quit.
May 20th, 2013
Selections from Richard Lehman’s Literature Review: May 20th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the safety and efficacy of sitagliptin for type 2 diabetes, use of glucocorticoids and the risk of VTE, and forced smoking abstinence.
March 18th, 2013
Selections from Richard Lehman’s Literature Review: March 18th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the association between smoking cessation and weight change with CV disease among those with and without diabetes, the risk of ischemic heart disease in women after radiotherapy for breast cancer, and more.
December 12th, 2012
FDA: Small, Nonsignificant Risk from Chantix
Larry Husten, PHD
The FDA today updated its safety review of the smoking cessation drug varenicline (Chantix, Pfizer). A large meta-analysis, which the FDA had required Pfizer to perform, found a higher rate of major adverse cardiovascular events (MACE) in patients taking varenicline than in patients taking placebo. However, the increase in risk was very small and did not achieve statistical significance. […]
August 8th, 2012
Selections from Richard Lehman’s Literature Review: August 8th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include heart failure and depression, endoscopic vs. open vein-graft harvest for CABG, linagliptin vs. glimepiride in those with type-2 diabetes, weight gain with smoking cessation, ACE inhibitors and pneumonia risk, and the effect of speech therapy after stroke.
May 14th, 2012
Selections from Richard Lehman’s Literature Review: Week of May 14th
Richard Lehman, BM, BCh, MRCGP
This week Richard discusses studies of glucose, insulin, and potassium for MI, elective PCI with and without surgical standby, and varenicline and CV risk.